VTRS Quote, Financials, Valuation and Earnings

BioCryst Pharmaceuticals, Inc. has a net margin of -3.41% compared to Viatris, Inc.'s net margin of 8.09%. Viatris, Inc.'s return on equity of -21.75% beat BioCryst Pharmaceuticals, Inc.'s return on equity of --.

Viatris, Inc. has a consensus price target of $12.1250, signalling upside risk potential of 11.85%. On the other hand BioCryst Pharmaceuticals, Inc. has an analysts' consensus of $20.40 which suggests that it could grow by 160.54%. Given that BioCryst Pharmaceuticals, Inc. has higher upside potential than Viatris, Inc., analysts believe BioCryst Pharmaceuticals, Inc. is more attractive than Viatris, Inc..

Viatris, Inc. has a beta of 0.843, which suggesting that the stock is 15.721% less volatile than S&P 500. In comparison BioCryst Pharmaceuticals, Inc. has a beta of 0.909, suggesting its less volatile than the S&P 500 by 9.061%.

Viatris, Inc. has a quarterly dividend of $0.12 per share corresponding to a yield of 4.43%. BioCryst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris, Inc. pays 90.63% of its earnings as a dividend. BioCryst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Viatris, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Viatris, Inc. quarterly revenues are $3.8B, which are larger than BioCryst Pharmaceuticals, Inc. quarterly revenues of $159.4M. Viatris, Inc.'s net income of -$128.2M is lower than BioCryst Pharmaceuticals, Inc.'s net income of $12.9M. Notably, Viatris, Inc.'s price-to-earnings ratio is -- while BioCryst Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris, Inc. is 0.91x versus 2.81x for BioCryst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Indivior PLC has a net margin of -3.41% compared to Viatris, Inc.'s net margin of 13.38%. Viatris, Inc.'s return on equity of -21.75% beat Indivior PLC's return on equity of 14.29%.

Viatris, Inc. has a consensus price target of $12.1250, signalling upside risk potential of 11.85%. On the other hand Indivior PLC has an analysts' consensus of $37.86 which suggests that it could grow by 9.41%. Given that Viatris, Inc. has higher upside potential than Indivior PLC, analysts believe Viatris, Inc. is more attractive than Indivior PLC.

Viatris, Inc. has a beta of 0.843, which suggesting that the stock is 15.721% less volatile than S&P 500. In comparison Indivior PLC has a beta of 1.102, suggesting its more volatile than the S&P 500 by 10.185%.

Viatris, Inc. has a quarterly dividend of $0.12 per share corresponding to a yield of 4.43%. Indivior PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris, Inc. pays 90.63% of its earnings as a dividend. Indivior PLC pays out -- of its earnings as a dividend. Viatris, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Viatris, Inc. quarterly revenues are $3.8B, which are larger than Indivior PLC quarterly revenues of $314M. Viatris, Inc.'s net income of -$128.2M is lower than Indivior PLC's net income of $42M. Notably, Viatris, Inc.'s price-to-earnings ratio is -- while Indivior PLC's PE ratio is 34.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris, Inc. is 0.91x versus 3.70x for Indivior PLC. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of -3.41% compared to Viatris, Inc.'s net margin of -19.69%. Viatris, Inc.'s return on equity of -21.75% beat Moderna, Inc.'s return on equity of -30.18%.

Viatris, Inc. has a consensus price target of $12.1250, signalling upside risk potential of 11.85%. On the other hand Moderna, Inc. has an analysts' consensus of $35.78 which suggests that it could grow by 40.36%. Given that Moderna, Inc. has higher upside potential than Viatris, Inc., analysts believe Moderna, Inc. is more attractive than Viatris, Inc..

Viatris, Inc. has a beta of 0.843, which suggesting that the stock is 15.721% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.

Viatris, Inc. has a quarterly dividend of $0.12 per share corresponding to a yield of 4.43%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris, Inc. pays 90.63% of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend. Viatris, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Viatris, Inc. quarterly revenues are $3.8B, which are larger than Moderna, Inc. quarterly revenues of $1B. Viatris, Inc.'s net income of -$128.2M is higher than Moderna, Inc.'s net income of -$200M. Notably, Viatris, Inc.'s price-to-earnings ratio is -- while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris, Inc. is 0.91x versus 4.42x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -3.41% compared to Viatris, Inc.'s net margin of 21.32%. Viatris, Inc.'s return on equity of -21.75% beat Pfizer Inc.'s return on equity of 10.84%.

Viatris, Inc. has a consensus price target of $12.1250, signalling upside risk potential of 11.85%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13%. Given that Pfizer Inc. has higher upside potential than Viatris, Inc., analysts believe Pfizer Inc. is more attractive than Viatris, Inc..

Viatris, Inc. has a beta of 0.843, which suggesting that the stock is 15.721% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Viatris, Inc. has a quarterly dividend of $0.12 per share corresponding to a yield of 4.43%. Pfizer Inc. offers a yield of 6.69% to investors and pays a quarterly dividend of $0.43 per share. Viatris, Inc. pays 90.63% of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend. Viatris, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer Inc.'s is not.

Viatris, Inc. quarterly revenues are $3.8B, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Viatris, Inc.'s net income of -$128.2M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Viatris, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris, Inc. is 0.91x versus 2.34x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.